|Address||24, Yeoui-daero, Yeongdeungpo-gu, Seoul, Republic of Korea|
SERVIER is an international pharmaceutical company governed by a non-profit foundation, with its headquarters in France. With a strong international presence in 149 countries. Entirely independent, the Group invests on average 25% of its total revenue (excluding generics) every year in research and development and uses all its profits for its development. Corporate growth is driven by Servier’s constant search for innovation in five areas of excellence: cancer, immune-inflammatory, neurodegenerative diseases, cardiovascular and diabetes, as well as by its activities in high-quality generic drugs. Servier also offers eHealth solutions beyond drug development.
ONIVYDE(liposomal irinotecan) is indicated, in combination with fluorouracil(5-FU) and leucovorin(LV), for the treatment of patients with metastatic adenocarcinoma of the pancreas after disease progression following gemcitabine-based therapy. In NCCN guideline, ONIVYDE+5-FU/LV is recommended a category 1 option for patients with post-gemcitabine metastatic pancreatic cancer with good performance status and disease progression.